These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37672049)

  • 21. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current pharmacotherapeutic treatment options in Parkinson's disease.
    Rezak M
    Dis Mon; 2007 Apr; 53(4):214-22. PubMed ID: 17586328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
    Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infusion Therapies in the Treatment of Parkinson's Disease.
    van Laar T; Chaudhuri KR; Antonini A; Henriksen T; Trošt M
    J Parkinsons Dis; 2023; 13(5):641-657. PubMed ID: 37334617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
    J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC; Hauser RA
    Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Senek M; Nielsen EI; Nyholm D
    Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Old Drugs, New Delivery Systems in Parkinson's Disease.
    Gupta HV; Lyons KE; Pahwa R
    Drugs Aging; 2019 Sep; 36(9):807-821. PubMed ID: 31161581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
    Marano M; Naranian T; di Biase L; Di Santo A; Poon YY; Arca R; Cossu G; Marano P; Di Lazzaro V; Fasano A
    Parkinsonism Relat Disord; 2019 Dec; 69():140-146. PubMed ID: 31759188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.